NEW YORK (GenomeWeb) – Molecular diagnostics firms Foundation Medicine and Guardant Health both announced today that they are partnering with Mirati Therapeutics to use their assays to select lung cancer patients for a Phase 2 clinical trial of Mirati's investigational drug glesatinib. The collaborations also pave the way for development of the technologies as companion diagnostics to the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.